MarketPulse
securities fraudclass action lawsuitshareholder rights

Schall Law Firm Opens Class Action Against Inovio Over Manufacturing Claims

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

Schall Law Firm launches class action against Inovio Pharmaceuticals for alleged misrepresentations about manufacturing capabilities and regulatory timelines. Investors can join until April 7, 2026.

Schall Law Firm Opens Class Action Against Inovio Over Manufacturing Claims
$INOnegative

The Schall Law Firm has initiated a securities litigation effort against Inovio Pharmaceuticals, Inc., inviting investors to join a class action lawsuit alleging material misrepresentations regarding the company's manufacturing capabilities and regulatory timeline projections.

The lawsuit centers on claims that Inovio made false or misleading statements concerning deficiencies in its CELLECTRA device manufacturing processes and the feasibility of submitting a Biologics License Application for INO-3107 by the second half of 2024. Securities purchased between October 10, 2023 and December 26, 2025 fall within the class period for the alleged misconduct.

Investors seeking to participate in the litigation must act before the April 7, 2026 deadline. The Schall Law Firm is accepting inquiries from shareholders who believe they suffered losses as a result of the company's alleged disclosures or omissions during the specified timeframe.

Topics

securities fraudclass action lawsuitshareholder rightsFDA approvalCELLECTRA devicemanufacturing deficienciesINO-3107 BLA

Source: GlobeNewswire Inc.

Back to newsPublished Feb 17

Related Coverage

GlobeNewswire Inc.

FDA Expands VYVGART Approval to All Generalized Myasthenia Gravis Patients

FDA expands VYVGART approval to include seronegative myasthenia gravis patients, broadening treatment access and increasing commercial opportunity for Ultragenyx.

ARGX
GlobeNewswire Inc.

FSK Securities Fraud Lawsuit: Investors Sought for Class Action Over Misleading Statements

Schall Law Firm seeks $FSK investors for class action lawsuit alleging false statements on portfolio restructuring, valuations, and dividend strength between May 2024 and February 2026.

FSK
GlobeNewswire Inc.

Securities Fraud Investigations Target LKQ, Molina, MongoDB, and Power Solutions

Grabar Law Office investigates four companies for alleged securities fraud involving false statements about business performance, causing stock price inflation and investor losses.

MOHLKQMDB
GlobeNewswire Inc.

POET Technologies Hit with Securities Fraud Lawsuit Over PFIC Disclosure Failures

Kirby McInerney LLP files class action against POET Technologies for alleged securities fraud involving PFIC misrepresentation and confidentiality breaches, triggering steep stock declines.

POET
GlobeNewswire Inc.

LakeShore Biopharma Faces Securities Probe Over Alleged Misleading Statements

The Schall Law Firm investigates LakeShore Biopharma for alleged securities violations, including false statements and material information failures, recruiting affected shareholders.

LSBCF
GlobeNewswire Inc.

CCRN Under Investigation for Alleged Securities Violations

Schall Law Firm investigates Cross Country Healthcare ($CCRN) for alleged securities violations involving false statements or material disclosure failures to investors.

CCRN